The Biohaven spinoff has picked up $60m in its series A round as it expects to increase its headcount tenfold.
Bioshin, a China-focused commercialisation spinout of drug developer Biohaven Pharmaceuticals, has raised $60m in series A funding led by biopharmaceuticals-focused investment firm OrbiMed.
The round was filled out by Cormorant Asset Management, HBM Healthcare Investments, Surveyor Capital and Suvretta Capital Management.
Bioshin was formed in 2018 to supervise the Chinese registration of Biohaven’s neurological and neuropsychiatric drug candidates through late clinical development which target two transmitters – CGRP and glutamate – linked to neurological pain.
The pipeline includes Nurtec, a…
